Takeda Pharmaceutical Co ADR (NYSE: TAK) has a price-to-earnings ratio of 22.49x that is above its average ratio. Additionally, the 36-month beta value for TAK is 0.54. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TAK is 3.17B and currently, short sellers hold a 0.19% ratio of that float. The average trading volume of TAK on November 14, 2024 was 1.64M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TAK) stock’s latest price update
The stock of Takeda Pharmaceutical Co ADR (NYSE: TAK) has increased by 0.15 when compared to last closing price of 13.54. Despite this, the company has experienced a -1.67% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-31 that Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O’Reilly – Head, Investor Relations Christophe Weber – President and Chief Executive Officer Milano Furuta – Chief Financial Officer Andy Plump – President, R&D Ramona Sequeira – President, Global Portfolio Julie Kim – President, U.S. Business Unit Giles Platford – President, PDT Business Unit Teresa Bitetti – President, Global Oncology Business Unit Conference Call Participants Steve Barker – Jefferies Mike Nedelcovych – TD Cowen Tony Ren – Macquarie Miki Sogi – Bernstein Christopher O’Reilly Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I’m the master of ceremony, Head of IR.
TAK’s Market Performance
Takeda Pharmaceutical Co ADR (TAK) has experienced a -1.67% fall in stock performance for the past week, with a -3.49% drop in the past month, and a -6.09% drop in the past quarter. The volatility ratio for the week is 0.86%, and the volatility levels for the past 30 days are at 1.08% for TAK. The simple moving average for the past 20 days is -2.37% for TAK’s stock, with a -2.57% simple moving average for the past 200 days.
Analysts’ Opinion of TAK
Many brokerage firms have already submitted their reports for TAK stocks, with BofA Securities repeating the rating for TAK by listing it as a “Buy.” The predicted price for TAK in the upcoming period, according to BofA Securities is $20 based on the research report published on March 16, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see TAK reach a price target of $24, previously predicting the price at $21. The rating they have provided for TAK stocks is “Outperform” according to the report published on July 19th, 2022.
TAK Trading at -5.14% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.08% of loss for the given period.
Volatility was left at 1.08%, however, over the last 30 days, the volatility rate increased by 0.86%, as shares sank -3.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.48% lower at present.
During the last 5 trading sessions, TAK fell by -1.67%, which changed the moving average for the period of 200-days by -6.74% in comparison to the 20-day moving average, which settled at $13.89. In addition, Takeda Pharmaceutical Co ADR saw -4.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from Giles Richard Platford, who proposed sale 19,073 shares at the price of $14.94 back on Aug 23 ’24. After this action, Giles Richard Platford now owns shares of Takeda Pharmaceutical Co ADR, valued at $284,951 using the latest closing price.
TAKEDA PHARMACEUTICAL CO LTD, the 10% Owner of Takeda Pharmaceutical Co ADR, sale 3,703,703 shares at $8.10 during a trade that took place back on Jan 24 ’24, which means that TAKEDA PHARMACEUTICAL CO LTD is holding 3,755,583 shares at $29,999,994 based on the most recent closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.62 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.03. The total capital return value is set at 0.03. Equity return is now at value 4.02, with 1.91 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.14. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is 1.86.
Currently, EBITDA for the company is 1.25 trillion with net debt to EBITDA at 5.22. When we switch over and look at the enterprise to sales, we see a ratio of 2.58. The receivables turnover for the company is 5.84for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
In conclusion, Takeda Pharmaceutical Co ADR (TAK) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
